Announcement

10.03.2011

In accordance with section 27b of Consolidated Act about Securities Trading
etc., we hereby issue a complete list of NeuroSearch announcements from January
2010 to March 2011. All announcements are available under the IR section of the
company's website: www.neurosearch.com.

Date No. Title
--------------------------------------------------------------------------------
03.02.2010 01-10 NeuroSearch announces positive top-line results from Phase
III Huntexil® study in Huntington's disease (the MermaiHD
study)
--------------------------------------------------------------------------------
11.02.2010 02-10 NeuroSearch presents additional data from the MermaiHD study
with Huntexil® at the 5th Annual CHDI Conference on
Huntington's disease
--------------------------------------------------------------------------------
08.03.2010 03-10 NeuroSearch announces new findings from the MermaiHD Phase
III study supporting potential disease modifying properties
of Huntexil®
--------------------------------------------------------------------------------
10.03.2010 04-10 NeuroSearch A/S - Financial statements 2009
--------------------------------------------------------------------------------
10.03.2010 05-10 List of NeuroSearch announcements in 2009 and in January -
March 2010
--------------------------------------------------------------------------------
16.03.2010 06-10 NeuroSearch issues new shares in connection with the exercise
of warrants
--------------------------------------------------------------------------------
22.03.2010 07-10 NeuroSearch issues new shares in connection with the exercise
of warrants
--------------------------------------------------------------------------------
31.03.2010 08-10 NeuroSearch A/S - Share capital and voting rights
--------------------------------------------------------------------------------
06.04.2010 09-10 Notice convening Annual General Meeting in NeuroSearch A/S
--------------------------------------------------------------------------------
06.04.2010 10-10 Notice convening Extraordinary General Meeting in NeuroSearch
A/S
--------------------------------------------------------------------------------
28.04.2010 11-10 NeuroSearch A/S announces the results of additional
assessment and analysis of data from the Phase III MermaiHD
study with Huntexil® in Huntington's disease
--------------------------------------------------------------------------------
28.04.2010 12-10 NeuroSearch A/S - Interim report for Q1 2010
--------------------------------------------------------------------------------
28.04.2010 13-10 Report on Ordinary General Meeting held in NeuroSearch A/S
--------------------------------------------------------------------------------
03.05.2010 14-10 Report on Extraordinary General Meeting held in NeuroSearch
A/S
--------------------------------------------------------------------------------
31.05.2010 15-10 NeuroSearch announces that CEO Flemming Pedersen resigns to
take up a new position
--------------------------------------------------------------------------------
10.08.2010 16-10 NeuroSearch announces that 27%-owned NsGene A/S signs new
agreement with Biogen Idec on therapeutic protein,
Neublastin
--------------------------------------------------------------------------------
24.08.2010 17-10 NeuroSearch names Patrik Dahlen as the company's new CEO
--------------------------------------------------------------------------------
25.08.2010 18-10 NeuroSearch A/S - Interim report for H1 2010
--------------------------------------------------------------------------------
04.09.2010 19-10 NeuroSearch announces the issuance of an EHDN statement
supporting the statistical conclusions on the primary
endpoint of the MermaiHD study
--------------------------------------------------------------------------------
15.09.2010 20-10 NeuroSearch announces results from an open-label safety
extension to the Phase III MermaiHD study of Huntexil® in
patients with Huntington's disease
--------------------------------------------------------------------------------
14.10.2010 21-10 The HART study with Huntexil® shows significant effect on
total motor function in patients with Huntington's disease
although it did not meet the primary endpoint after 12 weeks
of treatment
--------------------------------------------------------------------------------
19.10.2010 22-10 NeuroSearch announces revised financial calendar for 2010
--------------------------------------------------------------------------------
18.11.2010 23-10 NeuroSearch A/S - Interim report for Q3 2010
--------------------------------------------------------------------------------
01.12.2010 24-10 NeuroSearch appoints temporary Chief Medical Officer
--------------------------------------------------------------------------------
17.12.2010 25-10 NeuroSearch - Financial calendar for 2011
--------------------------------------------------------------------------------
30.12.2010 26-10 NeuroSearch announces the results of a meta-analysis of data
from a clinical Phase II/III programme with Huntexil® for
Huntington's disease
--------------------------------------------------------------------------------
10.01.2011 01-11 ATP, AES and SUPP's ownership in NeuroSearch has been reduced
to less than 10%
--------------------------------------------------------------------------------
11.01.2011 02-11 NeuroSearch announces a restructuring of the company to
support and strengthen strategic focus
--------------------------------------------------------------------------------
23.01.2011 03-11 NeuroSearch A/S - Annual General Meeting
--------------------------------------------------------------------------------
10.03.2011 04-11 NeuroSearch A/S - Financial statements and release of Annual
Report 2010
--------------------------------------------------------------------------------

Patrik Dahlen
CEO

Contact person:
René Schneider, EVP & CFO, telephone: +45 4460 8700


About NeuroSearch A/S
NeuroSearch A/S is a European based biopharmaceutical company, specialising in
CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a
pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique
orphan drug in Phase III for the treatment of Huntington's disease. NeuroSearch
is building commercial competences with a view to commercialising Huntexil®
through an in-house marketing and sales organisation.

NeuroSearch has a well-established drug discovery division, NsDiscovery, with
unique capabilities in the field of ion channels and CNS diseases. The company
has strategic drug discovery and development alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
NeuroSearch also has equity interests in a number of unlisted companies in the
Life Science industry.